COMPANY:

BD Biosci

"BD (Becton, Dickinson and Company)...announced U.S. Food and Drug Administration (FDA) market approval for the BD Onclarity™ HPV Assay to be used with the ThinPrep® Pap Test...The inclusion of the ThinPrep® Pap Test improves access to the benefits of the BD human papillomavirus virus (HPV) assay, which is the only FDA-approved assay that tests for an extended set of HPV types individually, and particularly for HPV31, a specific type of HPV that poses a high-risk for causing cervical cancer."

"BD (Becton, Dickinson and Company)...announced a collaboration agreement with Labcorp...creating a framework to develop, manufacture, market and commercialize flow cytometry-based companion diagnostics (CDx) intended to match patients with life-changing treatments for cancer and other diseases...The agreement creates a framework for BD and Labcorp Drug Development to collaborate on flow cytometry-based CDx opportunities with pharmaceutical partners. The two companies bring together capabilities that comprise an end-to-end solution for CDx development for the pharmaceutical industry."

"BD (Becton, Dickinson and Company)...announced it has completed the acquisition of Cytognos, a privately held company headquartered in Salamanca, Spain, specializing in flow cytometry solutions for blood cancer diagnosis, minimal residual disease (MRD) detection and immune monitoring research for blood diseases...Cytognos' key products increase BD's comprehensive portfolio of diagnostic and research solutions for certain types of cancers that use flow cytometry as the primary means of discovery, diagnosis and understanding, including lymphoma, leukemia and multiple myeloma."

'Becton Dickinson announced Wednesday that it has received US Food and Drug Administration approval for its automated, sample-to-answer, high-throughput BD Cor system along with its Onclarity human papillomavirus extended genotyping assay."